UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

Form 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 12, 2020  

Atreca, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware001-3893527-3723255
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)

 

450 East Jamie Court, South San Francisco, California94080
(Address of Principal Executive Offices)(Zip Code)

(650) 595-2595
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 [   ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 [   ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 [   ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 [   ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share BCEL The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

 
 

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2020, Atreca, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2020 and its recent corporate developments. A copy of such press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, or into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit Number Exhibit Description
   
99.1 Press Release titled “Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments,” dated August 12, 2020, furnished herewith


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Atreca, Inc.
   
  
Dated: August 12, 2020By: /s/ Herbert Cross        
  Herbert Cross
  Chief Financial Officer
  

EdgarFiling

EXHIBIT 99.1

Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

“The second quarter was eventful for Atreca as we continue to execute on our various development objectives,” said John Orwin, Chief Executive Officer. “We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase 1b first-in-human study evaluating ATRC-101 continues to enroll patients and now has five trial sites active. In addition, our recently announced strategic collaboration with Xencor to develop bispecific T cell-engaging antibodies underscores the value of novel targets in oncology and the ability of our technology platform to attract weaponization partners. We believe these milestones, coupled with our strengthened financial position from the completion an equity financing in July, position us well for continued progress in the second half of 2020.”

Recent Developments and Highlights

Second Quarter 2020 Financial Results

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “will”, “believe,” “potential,” “continue,” “expects,” “planned,” “may,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Atreca, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)

      
 June 30,  December 31,  
 2020  2019 
      
ASSETS     
      
Current Assets
Cash and cash equivalents$  100,430  $  157,954 
Investments  43,088    14,663 
Prepaid expenses and other current assets  5,112    3,502 
Total current assets  148,630    176,119 
Property and equipment, net  7,666    5,771 
Long-term investments  5,311    10,799 
Deposits and other  2,934    3,026 
Total assets$  164,541  $  195,715 
      
LIABILITIES AND STOCKHOLDERS’ EQUITY
      
Current Liabilities
Accounts payable $  1,060  $  2,133 
Accrued expenses  4,434    5,395 
Other current liabilities  1,859    419 
Total current liabilities  7,353    7,947 
Capital lease obligations, net of current portion  29    53 
Deferred rent  2,887    763 
Other non-current liabilities  157    -  
Total liabilities  10,426    8,763 
      
      
Stockholders’ equity
Common stock  3    3 
Additional paid-in capital  358,401    351,039 
Accumulated other comprehensive income  216    16 
Accumulated deficit  (204,505)   (164,106)
Total stockholders’ equity   154,115    186,952 
Total liabilities and stockholders’ equity $  164,541  $  195,715 
      


Atreca, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)

($ amounts in 000's, except per share amounts)           
             
  Three Months Ended
  Six Months Ended
 
  June 30,
  June 30,
 
  2020  2019  2020  2019 
Expenses           
 Research and development$  14,180  $  15,922  $  28,390  $  27,635 
 General and administrative  6,458    3,537    13,581    6,055 
 Total expenses  20,638    19,459    41,971    33,690 
Interest and other income (expense)           
 Other income  403    1,021    634    1,186 
 Interest income  255    594    940    1,139 
 Interest expense  (1)   (2)   (2)   (4)
 Preferred stock warrant liability revaluation  —     (73)   —     (123)
 Loss on disposal of property and equipment  —     (2)   —     (7)
Loss before Income tax expense  (19,981)   (17,921)   (40,399)   (31,499)
Income tax expense  -     -     -     (1) 
Net loss$  (19,981) $  (17,921) $  (40,399) $  (31,500)
Net loss per share, basic and diluted$  (0.71) $  (3.67) $  (1.44) $  (8.97)
Weighted-average shares used in computing            
net loss per share, basic and diluted  28,144,714    4,888,987    28,082,930    3,512,606 
             


Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com